CoChat
Sign Up
Cited by 180Treatment of Major DepressionChild and Adolescent Psychosocial and Emotional DevelopmentMental Health Treatment and Access

The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

Open access
Hetrick, Sarah E, Merry, Sally N, McKenzie, Joanne, Sindahl, Per, Proctor, Michelle·2007·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd004851.pub2
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Depressive disorders are common in young people and are associated with significant negative impacts. Selective serotonin reuptake inhibitors (SSRIs) are often used, however, evidence of their effectiveness in children and adolescents is not clear. Furthermore, there have been warnings against their use in this population due to concerns about increased risk of suicidal ideation and behaviour. OBJECTIVES: To determine the efficacy and adverse outcomes, including definitive suicidal behaviour and suicidal ideation, of SSRIs compared to placebo in the treatment of depressive disorders in children and adolescents. SEARCH STRATEGY: We searched the CCDAN Trials Register, MEDLINE, PSYCHINFO and CENTRAL. Reference lists were checked, letters were sent to key researchers and internet databases searched. SELECTION CRITERIA: We included published and unpublished randomised controlled trials. DATA COLLECTION AND ANALYSIS: Two or three review authors selected the trials, assessed the quality and extracted trial and outcome data. We used a fixed-effect meta-analysis. The relative risk was used to summarise dichotomous outcomes and the mean difference to summarise continuous measures. MAIN RESULTS: Twelve trials were eligible for inclusion, with ten providing usable data. At 8-12 weeks, there was evidence that children and adolescents 'responded' to treatment with SSRIs (RR 1.28, 95% CI 1.17 to 1.41). There was also evidence of an increased risk of suicidal ideation and behaviour for those prescribed SSRIs (RR 1.80, 95% CI 1.19 to 2.72). Fluoxetine was the only SSRI where there was consistent evidence from three trials that it was effective in reducing depression symptoms in both children and adolescents (CDRS-R treatment effect -5.63, 95% CI -7.38 to -3.88), and 'response' to treatment (RR 1.86, 95% CI 1.49 to 2.32). Where rates of adverse events were reported, this was higher for those prescribed SSRIs. AUTHORS' CONCLUSIONS: Caution is required to interpret the results. First, there were methodological issues, including high attrition, issues regarding measurement instruments and clinical usefulness of outcomes, often variously defined across trials. Second, patients seen in clinical practice are likely to be more unwell, and at greater risk of suicide, compared to those in the trials, and it is unclear how this group would respond to SSRIs. This needs to be considered, along with the evidence of an increased risk of suicide related outcomes in those treated with SSRIs. It is unclear what the effect of SSRIs is on suicide completion. While untreated depression is associated with the risk of completed suicide and impacts on functioning, it is unclear whether SSRIs would modify this risk in a clinically meaningful way.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004851.pub2

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Research works printed but not linked: 10

  1. Mandoki, 1997, Vanlafaxine in the treatment of children and adolescents with major depression, Psychopharmacology Bulletin, 33, 149
  2. Dubitsky GM Review and Evaluation of Clinical Data: Placebo-Controlled Antidepressant Studies In Pediatric Patients Medicines and Healthcare Products Regulatory Agency
  3. Essau, 1999, In FPCA Essau (Ed). Depressive Disorders in Children and Adolescents: Epidemiology, Risk Factors and Treatment (p 326)
  4. Jureidini J Tonkin A Paroxetine in major depression Journal of the American Academy of Child and Adolescent Psychiatry 2003 514 · DOI
  5. Moncrieff, 2005, Active placebo versus antidepressants for depression, Cochrane Database of Systematic Reviews
  6. Murray, 1996, The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020
  7. 1997, Depression in young people: Clinical Practice Guidelines
  8. 2005, Depression in Children and Young People: Identification and management in primary, community and secondary care
  9. Petti, 1985, Scales of potential use in the psychopharmacological treatment of depressed children and adolescents, Psychopharmacology Bulletin, 21, 951
  10. The Nortic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2003

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Hetrick, S. E., Merry, S. N., McKenzie, J., Sindahl, P., & Proctor, M.
Affiliations
  • The University of Melbourne (AU)
  • University of Auckland (NZ)
  • Monash University (AU)
ORCID
Venue
Cochrane Database of Systematic Reviews
Publisher
John Wiley & Sons, Ltd
Published
2007-07-18
Issue
3
Pages
CD004851-CD004851
ISSN
1361-6137 (ISSN-L)
DOI
10.1002/14651858.cd004851.pub2
OpenAlex
W1935785240
Cited by
180
References
114
Citations by year
2026: 3 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 1 · 2017: 5 · 2016: 14 · 2015: 5 · 2014: 11 · 2013: 15 · 2012: 27
Type
reference entry
Language
en
Update notices
new_version (2012-11-14)
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • ResearchSpace (University of Auckland) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
selective serotonin reuptake inhibitors, childhood depression, adolescent depression, suicidal ideation, suicidal behavior, fluoxetine, antidepressant efficacy, adverse drug reactions, treatment response, placebo comparison, antidepressant-induced mania
MeSH terms
Adolescent, Antidepressive Agents, Child, Depressive Disorder, Fluoxetine, Humans, Suicide, Citalopram, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review